Rapid and robust pipeline for developing mRNA vaccines for future SARS-CoV-2 variants SARSCoV2 Coronavirus Disease COVID mRNA Vaccines ResearchSquare
By Dr. Priyom Bose, Ph.D.Oct 19 2022Reviewed by Aimee Molineux Severe acute respiratory syndrome coronavirus-2 , the causal agent of the ongoing coronavirus disease 2019 pandemic, has claimed more than 6.5 million lives worldwide. The genomic evolution of the virus has led to the rapid emergence of new SARS-CoV-2 strains, and several of these variants are more infectious and virulent compared to the ancestral strain.
Background To date, all the available COVID-19 vaccines and therapeutics have been developed based on the spike protein of the ancestral SARS-CoV-2 strain. Therefore, reduced efficacy of COVID-19 vaccines and therapeutics was observed against SARS-CoV-2 variants containing mutations in the spike region. As a result, the scientific community has been working relentlessly to develop effective vaccines and therapeutics to combat newly emerged SARS-CoV-2 variants.
The second vertical is the neutralization assay using the pseudo-/surrogate-typed virus. This assay helps determine the efficacy of neutralizing antibodies in the sera of vaccinated humans/animals. Finally, the third vertical of the mRNA portfolio are recombinant proteins, which are used to fabricate various immunological assays to quantify the functional immune response in the sera of vaccinated humans/animals.
Various PCR factors were optimized, such as the annealing temperature of the oligonucleotides, concentration of the oligonucleotides, and PCR cycle temperature, for the favorable assembly of long oligonucleotides.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Met Police chief warns officers that they'll be sacked for holding misogynist or racist viewsIn a leaked email, obtained by i, Sir Mark Rowley issued a stark warning following a scathing report that found Met officers kept their jobs after reports of sexual misconduct, misogyny and racism
Lire la suite »
Hesitancy for receiving regular SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis from the UK-REACH study - BMC MedicineBackground Regular vaccination against SARS-CoV-2 may be needed to maintain immunity in ‘at-risk’ populations, which include healthcare workers (HCWs). However, little is known about the proportion of HCWs who might be hesitant about receiving a hypothetical regular SARS-CoV-2 vaccination or the factors associated with this hesitancy. Methods Cross-sectional analysis of questionnaire data collected as part of UK-REACH, a nationwide, longitudinal cohort study of HCWs. The outcome measure was binary, either a participant indicated they would definitely accept regular SARS-CoV-2 vaccination if recommended or they indicated some degree of hesitancy regarding acceptance (probably accept or less likely). We used logistic regression to identify factors associated with hesitancy for receiving regular vaccination. Results A total of 5454 HCWs were included in the analysed cohort, 23.5% of whom were hesitant about regular SARS-CoV-2 vaccination. Black HCWs were more likely to be hesitant than White HCWs (aOR 2.60, 95%CI 1.80–3.72) as were those who reported a previous episode of COVID-19 (1.33, 1.13–1.57 [vs those who tested negative]). Those who received influenza vaccination in the previous two seasons were over five times less likely to report hesitancy for regular SARS-CoV-2 vaccination than those not vaccinated against influenza in either season (0.18, 0.14–0.21). HCWs who trusted official sources of vaccine information (such as NHS or government adverts or websites) were less likely to report hesitancy for a regular vaccination programme. Those who had been exposed to information advocating against vaccination from friends and family were more likely to be hesitant. Conclusions In this study, nearly a quarter of UK HCWs were hesitant about receiving a regular SARS-CoV-2 vaccination. We have identified key factors associated with hesitancy for regular SARS-CoV-2 vaccination, which can be used to identify groups of HCWs at the highest risk of vaccine hesitancy and tailor
Lire la suite »
Differential effects of SARS-CoV-2 variants on children and adolescentsA recent Emerging Infectious Diseases journal study evaluated whether specific SARS-CoV-2 variants were linked with different clinical manifestations in children and adolescents.
Lire la suite »
Scientists develop a pseudovirus system to deep mutational scan the full SARS-CoV-2 spikeScientists develop a pseudovirus system to deep mutational scan the full SARS-CoV-2 spike Coronavirus Disease COVID GenomicSequencing SARSCoV2 jbloom_lab biorxivpreprint
Lire la suite »
Study suggests relationship between maternal COVID vaccination, SARS-CoV-2 placentitis, and stillbirthStudy suggests relationship between maternal COVID vaccination, SARS-CoV-2 placentitis, and stillbirth Coronavirus Disease COVID Pregnancy SARSCoV2 placentitis Stillbirth GWtweets MassGeneralNews ChildrensNatl
Lire la suite »
Could COVID-19 infections trigger a relapse of mycosis fungoides or other cutaneous T-cell lymphomas?Recently, authors highlighted the potential role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in triggering the relapse of mycosis fungoides, a type of cutaneous T-cell lymphoma.
Lire la suite »